Fresenius Medical Care Management
Management criteria checks 2/4
Fresenius Medical Care's CEO is Helen Giza, appointed in Nov 2019, has a tenure of 5.08 years. total yearly compensation is €5.53M, comprised of 30.1% salary and 69.9% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth €606.39K. The average tenure of the management team and the board of directors is 2 years and 0.9 years respectively.
Key information
Helen Giza
Chief executive officer
€5.5m
Total compensation
| CEO salary percentage | 30.1% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.005% |
| Management average tenure | 2yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Here's What's Concerning About Fresenius Medical Care's (ETR:FME) Returns On Capital
Dec 22
What Is Fresenius Medical Care AG's (ETR:FME) Share Price Doing?
Nov 21Fresenius Medical Care AG (ETR:FME) Not Flying Under The Radar
Nov 01We Think Fresenius Medical Care (ETR:FME) Is Taking Some Risk With Its Debt
Sep 26These Return Metrics Don't Make Fresenius Medical Care (ETR:FME) Look Too Strong
Sep 08At €34.34, Is Fresenius Medical Care AG (ETR:FME) Worth Looking At Closely?
Aug 20Fresenius Medical Care AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 02These 4 Measures Indicate That Fresenius Medical Care (ETR:FME) Is Using Debt Extensively
Jun 17What You Can Learn From Fresenius Medical Care AG's (ETR:FME) P/E
May 30Some Shareholders May Object To A Pay Rise For Fresenius Medical Care AG's (ETR:FME) CEO This Year
May 10Fresenius Medical Care (ETR:FME) Is Increasing Its Dividend To €1.19
Apr 26Fresenius Medical Care's (ETR:FME) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 29Fresenius Medical Care (ETR:FME) Has Announced That It Will Be Increasing Its Dividend To €1.19
Mar 14Fresenius Medical Care's (ETR:FME) Dividend Will Be Increased To €1.19
Feb 23When Should You Buy Fresenius Medical Care AG (ETR:FME)?
Feb 22Market Participants Recognise Fresenius Medical Care AG's (ETR:FME) Earnings
Feb 03Fresenius Medical Care (ETR:FME) Could Be Struggling To Allocate Capital
Jan 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | €659m |
| Jun 30 2024 | n/a | n/a | €530m |
| Mar 31 2024 | n/a | n/a | €484m |
| Dec 31 2023 | €6m | €2m | €499m |
| Sep 30 2023 | n/a | n/a | €450m |
| Jun 30 2023 | n/a | n/a | €596m |
| Mar 31 2023 | n/a | n/a | €602m |
| Dec 31 2022 | €3m | €1m | €673m |
| Sep 30 2022 | n/a | n/a | €763m |
| Jun 30 2022 | n/a | n/a | €806m |
| Mar 31 2022 | n/a | n/a | €878m |
| Dec 31 2021 | €2m | €855k | €969m |
| Sep 30 2021 | n/a | n/a | €918m |
| Jun 30 2021 | n/a | n/a | €998m |
| Mar 31 2021 | n/a | n/a | €1b |
| Dec 31 2020 | €2m | €855k | €1b |
| Sep 30 2020 | n/a | n/a | €1b |
| Jun 30 2020 | n/a | n/a | €1b |
| Mar 31 2020 | n/a | n/a | €1b |
| Dec 31 2019 | €2m | €108k | €1b |
Compensation vs Market: Helen's total compensation ($USD5.78M) is about average for companies of similar size in the German market ($USD4.79M).
Compensation vs Earnings: Helen's compensation has increased by more than 20% in the past year.
CEO
Helen Giza (56 yo)
5.1yrs
Tenure
€5,528,000
Compensation
Ms. Helen Giza is Chief Executive Officer and Chair of the Management Board of Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & Co. KGAA from December 6, 2022. She serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chair of Management Board & CEO | 5.1yrs | €5.53m | 0.0047% € 606.4k | |
| CFO & Member of the Management Board | 1.2yrs | €887.00k | no data | |
| Global Chief Medical Officer & Member of Management Board | 4.9yrs | €3.13m | 0.0062% € 800.8k | |
| CEO of Care Enablement & Member of Management Board | 2.9yrs | €3.71m | 0.0039% € 501.4k | |
| CEO of Care Delivery & Member of Management Board | less than a year | no data | no data | |
| Executive VP and Head of Investor Relations | no data | no data | no data | |
| Global Head of Legal | less than a year | no data | no data | |
| Senior Vice President of Corporate Communications & Governmental Affairs | no data | no data | no data | |
| Senior Vice President of Research & Development | no data | no data | no data | |
| Senior Vice President of Manufacturing and Supply Chain Operations | no data | no data | no data | |
| Senior Vice President - Quality Management International | no data | no data | no data | |
| Executive Vice President of Western Europe & Nephrocare Coordination EMEALA | no data | no data | no data |
2.0yrs
Average Tenure
56.5yo
Average Age
Experienced Management: FME's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Member of Supervisory Board | 1.1yrs | €20.00k | no data | |
| Chairman of the Supervisory Board | 1.4yrs | €444.00k | no data | |
| Independent Member of Supervisory Board | 1.1yrs | €21.00k | no data | |
| Independent Member of Supervisory Board | 3.6yrs | €151.00k | no data | |
| Employee Representative Deputy Chairwoman of the Supervisory Board | less than a year | no data | no data | |
| Member of Supervisory Board | 1.1yrs | €158.00k | no data | |
| Employee Representative Member of Supervisory Board | less than a year | no data | no data | |
| Employee Representative Member of the Supervisory Board | less than a year | no data | no data | |
| Employee Representative Member of the Supervisory Board | less than a year | no data | no data | |
| Employee representatives Member of the Supervisory Board | less than a year | no data | no data | |
| Employee representatives Member of the Supervisory Board | less than a year | no data | no data |
0.9yrs
Average Tenure
56yo
Average Age
Experienced Board: FME's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 15:30 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fresenius Medical Care AG is covered by 58 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Brian Williams | Avondale Partners |
| Olav Zilian | Baader Helvea Equity Research |